Sur cette page
01ACAD prix
02Aperçu
03Graphique
05À propos
06Performance
07Valorisation et ratios
14Bénéfices
15Fondamentaux complets
16États financiers
17Détenteurs institutionnels (13F)
18Activistes et détenteurs de 5%+
19Initiés de la société
20Détention d'ETF
21Consensus
22Pairs
23Actualités
25Signaux de trading
26Mes métriques
ACAD ACADIA Pharmaceuticals Inc. - Common Stock
NASDAQ · Biotechnology · Voir sur SEC EDGAR ↗ clôture Oct 2, 2026 10-K/10-Q Aoû 5, 2026
$19,95
· % de la fourchette 52 sem.
· au-dessus du plus bas
· vers le haut
$19,59Bas 52 semaines
$30,96Haut 52 semaines
Capitalisation Boursière (MRQ)
$3.43B
P/E (TTM)
8.9
BPA (TTM)
$2.23
Revenu (TTM)
$1.14B
vos badges
Fourchette 52 semaines
$20–$31
Note des analystes
BUY
Objectif de cours
$32
P/E
8.9
ROE
35.7%
Marge nette
33.4%
Votre barre de badges est vide — épinglez une métrique n'importe où sur cette page.
ACAD Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$19.95
Capitalisation Boursière (MRQ)
$3.43B
P/E (TTM)
8.9
BPA (TTM)
$2.23
Revenu (TTM)
$1.14B
ROE (TTM)
35.7%
Fourchette 52 semaines
$20–$31
ACAD Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
fourchette
barres
La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.
À propos de ACADIA Pharmaceuticals Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Product development
Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.
Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis, major depressive disorder, schizophrenia inadequate response, and schizophrenia negative symptoms.
As of 1997, Acadia was among several companies that licensed compounds from Genzyme's small-molecule compound library.
In 2023, the FDA approved trofinetide (marketed as Daybue) for use in Rett syndrome.
History
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California, as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikring A/S and Dansk Kapitalanlæg Aktieselskab as well as private investor Lars Christiansen. At the time, the company had fifty employees, fourteen of whom were in the Denmark office. The focus of the company in its early years was on genetic screens for receptors, aiming to accelerate early stage drug discovery.
The company planned to conduct an initial public offering (IPO) consisting of 31.6% of the company in 2001, with the intention of raising US$64 million and listing on the NASDAQ exchange under the symbol ACAD. At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. However, the company's IPO, which ultimately took place in May 2004, did not fare as well as expected and netted only US$35 million. At the time, the company had five drugs in development and was running two in human trials. The company had a subsequent round of stock offering in May 2007 which raised US$102 million.
In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics.
Corporate governance
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
== References ==
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
secteurHealthcare
industrieBiotechnology
employés796
paysUS
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenu$1.07B2016-12-31 → 2025-12-31
BPA$2.302020-12-31 → 2025-12-31
Flux de trésorerie libre$105M2016-12-31 → 2025-12-31
Marge nette33.4%2016-12-31 → 2025-12-31
Valorisation et Ratios
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
| Métrique | Tendance sur 5 ans | ACAD | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 8.9moyenne 5 ans ≈-18.7 | ≈-18.7 | 13.8 | Sous-évalué | |
| P/S (TTM) | 3.0moyenne 5 ans ≈5.5 | ≈5.5 | 11.9 | Sous-évalué | |
| P/B (MRQ) | 2.6moyenne 5 ans ≈6.6 | ≈6.6 | 3.4 | Sous-évalué | |
| Cours / FCF (TTM) | 23.6moyenne 5 ans ≈64.0 | ≈64.0 | · | · | |
| Cours / Flux de trésorerie (TTM) | 21.4moyenne 5 ans ≈63.4 | ≈63.4 | · | · | |
| Cours / Actif net tangible (MRQ) | 2.9moyenne 5 ans ≈7.3 | ≈7.3 | · | · |
La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
| Métrique | Tendance sur 5 ans | ACAD | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Marge d'exploitation (TTM) | 7.6%moyenne 5 ans ≈-10.9% | ≈-10.9% | 12.5% | En ligne | |
| EBITDA Margin (Marge EBITDA) | 9.8%moyenne 5 ans ≈-10.9% | ≈-10.9% | 12.5% | En ligne | |
| Marge avant impôts (TTM) | 10.7%moyenne 5 ans ≈-8.6% | ≈-8.6% | 16.4% | En ligne | |
| Marge nette (TTM) | 33.4%moyenne 5 ans ≈-4.9% | ≈-4.9% | 10.2% | En ligne | |
| ROA (TTM) | 25.6%moyenne 5 ans ≈-2.7% | ≈-2.7% | -7.4% | Premier rang | |
| ROE (TTM) | 35.7%moyenne 5 ans ≈-5.1% | ≈-5.1% | -10.7% | Premier rang | |
| ROIC | 24.0%moyenne 5 ans ≈-11.4% | ≈-11.4% | -3.0% | Premier rang |
Santé financière Dette, liquidité, solvabilité — solidité du bilan
| Métrique | Tendance sur 5 ans | ACAD | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Ratio de liquidité (MRQ) | 3.4moyenne 5 ans ≈3.8 | ≈3.8 | 6.5 | Faible liquidité | |
| Quick Ratio (Ratio de liquidité réduite) | 1.1moyenne 5 ans ≈1.4 | ≈1.4 | 5.0 | Faible liquidité |
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
| Métrique | Tendance sur 5 ans | ACAD | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Revenue YoY (Chiffre d'affaires YoY) | 11.9%moyenne 5 ans ≈20.1% | ≈20.1% | · | · | |
| Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans) | 27.5%moyenne 5 ans ≈23.7% | ≈23.7% | · | · | |
| Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans) | 19.4% | · | · | · | |
| EPS YoY (BPA Année/Année) | 69.1% | · | · | · | |
| Net Income YoY (Bénéfice net YoY) | 72.7% | · | · | · |
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
| Métrique | Tendance sur 5 ans | ACAD | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Asset Turnover (Rotation des actifs) | 0.8moyenne 5 ans ≈0.9 | ≈0.9 | 0.4 | Premier rang | |
| Inventory Turnover (Rotation des stocks) | 0.9moyenne 5 ans ≈1.1 | ≈1.1 | · | · | |
| Receivables Turnover (Rotation des créances) | 9.7moyenne 5 ans ≈9.1 | ≈9.1 | 10.5 | En ligne | |
| Revenue / Employee (Chiffre d'affaires annuel ÷ employés (effectif déclaré, yfinance). Dérivé — pas un concept SEC-XBRL stocké.) | ≈$1.3M | · | · | · |
valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
228.8%
Prochain rapport
Nov 03, 2026
| Période | Rapport | EPS Actual | BPA est. | Surprise |
|---|---|---|---|---|
| 30 juin 2026 | Aoû 11, 2026 | $0.18 | $0.06 | 207.2% |
| 31 mars 2026 | Mai 13, 2026 | $0.02 | $0.06 | -68.4% |
| 31 décembre 2025 | $1.60 | $0.14 | 1044.5% | |
| 30 septembre 2025 | $0.42 | $0.15 | 178.1% | |
| 30 juin 2025 | $0.16 | $0.14 | 14.4% | |
| 31 mars 2025 | $0.11 | $0.11 | -3.2% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Cost of Revenue | $89M | $82M | $42M | $10M | $19M | $10M | $11M | $12M | $9M | $3M | · | · | |
| Gross Profit | · | · | $685M | $507M | $473M | $432M | $328M | $211M | $116M | $14M | · | · | |
| R&D Expense | $329M | $303M | $352M | $362M | $239M | $319M | $240M | $187M | $149M | $99M | $74M | $61M | |
| SG&A Expense | $549M | $488M | $407M | $369M | $396M | $389M | $326M | $266M | $255M | $186M | $88M | $33M | |
| Operating Expenses | $967M | $727M | $800M | $741M | $655M | $728M | $586M | $471M | $417M | $290M | $165M | $93M | |
| Operating Income | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M | |
| Other Non-op | $2M | $2M | $5M | $4M | $2M | $-997.0K | $997.0K | $-2M | · | · | · | · | |
| Pretax Income | $139M | $258M | $-51M | $-213M | $-168M | $-281M | $-234M | $-244M | $-288M | $-270M | $-164M | $-92M | |
| Income Tax | $-252M | $32M | $10M | $3M | $351.0K | $611.0K | $876.0K | $1M | $1M | $1M | $330.0K | $0 | |
| Net Income | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| EPS (Diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| Shares (Basic) | 168,356,000 | 165,717,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| Shares (Diluted) | 169,919,000 | 166,362,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| EBITDA | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M |
Bilan
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $178M | $320M | $189M | $115M | $147M | $326M | $190M | $135M | $69M | $164M | $102M | $62M | |
| Receivables | $121M | $99M | $98M | $62M | $64M | $48M | $36M | $26M | $17M | $6M | · | · | |
| Inventory | $111M | $92M | $40M | $12M | $14M | $10M | $6M | $4M | $5M | $4M | · | · | |
| Prepaid Expense | $60M | $56M | $39M | $21M | $24M | $26M | $19M | $21M | $8M | $8M | $2M | $1M | |
| Current Assets | $1.06B | $938M | $616M | $508M | $618M | $718M | $760M | $526M | $373M | $548M | $219M | $325M | |
| PP&E (Net) | $8M | $4M | $5M | $6M | $8M | $9M | $3M | $3M | $3M | $3M | $2M | $553.0K | |
| PP&E (Gross) | $17M | $14M | $14M | $14M | $14M | $13M | $9M | $8M | $7M | $6M | $5M | $3M | |
| Accum. Depreciation | $9M | $10M | $10M | $8M | $6M | $4M | $5M | $4M | $4M | $3M | $3M | $2M | |
| Intangibles | $109M | $120M | $65M | $0 | $0 | $1M | $3M | $4M | $6M | $7M | · | · | |
| Other Non-current Assets | $4M | $359.0K | $476.0K | $8M | $4M | $2M | $3M | $2M | $354.0K | $785.0K | $329.0K | $287.0K | |
| Total Assets | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Accounts Payable | $11M | $16M | $18M | $13M | $7M | $8M | $7M | $3M | $9M | $4M | $2M | $2M | |
| Accrued Liabilities | $266M | $379M | $237M | $113M | $89M | $97M | $68M | $56M | $40M | $36M | $20M | $14M | |
| Current Liabilities | $277M | $395M | $254M | $126M | $96M | $106M | $75M | $60M | $49M | $43M | $22M | $16M | |
| Capital Leases | $41M | $42M | $48M | $53M | $56M | $44M | $6M | · | · | · | · | · | |
| Deferred Tax | $11M | $11M | $12M | $13M | $14M | $13M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $19M | $18M | $15M | $9M | $7M | $5M | $3M | $2M | · | · | · | · | |
| Total Liabilities | $337M | $455M | $317M | $187M | $159M | $156M | $84M | $61M | $49M | $43M | $22M | $16M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $15.0K | $14.0K | $12.0K | $12.0K | $10.0K | $10.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | $1.45B | $862M | $808M | |
| Retained Earnings | $-1.81B | $-2.20B | $-2.43B | $-2.37B | $-2.15B | $-1.99B | $-1.70B | $-1.47B | $-1.22B | $-934M | $-663M | $-498M | |
| AOCI | $1M | $292.0K | $24.0K | $-975.0K | $-192.0K | $36.0K | $297.0K | $-372.0K | $-399.0K | $106.0K | $11.0K | $-9.0K | |
| Stockholders' Equity | $1.23B | $733M | $432M | $400M | $541M | $627M | $699M | $479M | $335M | $518M | $200M | $309M | |
| Liabilities + Equity | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Shares Outstanding | 170,309,376 | 166,708,856 | 164,650,219 | 162,064,872 | 161,012,695 | 159,637,771 | 155,275,300 | 143,853,597 | 124,410,552 | 121,367,169 | 101,938,702 | 100,047,331 |
Flux de trésorerie
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $206.0K | |
| Stock-based Comp | $52M | $67M | $66M | $68M | $64M | $84M | $82M | $82M | $76M | $55M | $40M | $16M | |
| Deferred Tax | $-250M | $0 | $0 | $3M | $351.0K | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $11M | $15M | $4M | $0 | $1M | $1M | $1M | $1M | $1M | $985.0K | $0 | $0 | |
| Operating Cash Flow | $110M | $158M | $17M | $-114M | $-126M | $-136M | $-151M | $-167M | $-218M | $-208M | $-122M | $-66M | |
| CapEx | $5M | $523.0K | $50.0K | $0 | $1M | $8M | $1M | $2M | $812.0K | $2M | $2M | $180.0K | |
| Investing Cash Flow | $-303M | $-31M | $32M | $73M | $-71M | $193M | $-166M | $-71M | $92M | $-262M | · | · | |
| Stock Issued | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Net Stock Activity | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Financing Cash Flow | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $534M | · | · | |
| Net Change in Cash | $-143M | $134M | $74M | $-33M | $-179M | $137M | $55M | $68M | $-94M | $63M | $40M | $50M | |
| Taxes Paid | $25M | $20M | $6M | $2M | $1M | $1M | $2M | $1M | $1M | $-365.0K | $415.0K | · | |
| Free Cash Flow | $105M | $157M | $17M | $-114M | $-127M | $-144M | $-152M | $-170M | $-219M | $-212M | $-124M | $-67M |
Rentabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% | · | · | |
| Operating Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| Net Margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% | -269578.7% | -77062.5% | |
| Pretax Margin | 13.0% | 26.9% | -7.0% | -41.3% | -34.6% | -63.6% | -69.1% | -109.0% | -230.8% | -1558.2% | -269037.7% | · | |
| EBITDA Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| ROA | 28.4% | 23.4% | -9.2% | -33.5% | -22.6% | -36.0% | -35.5% | -53.0% | -61.2% | -69.3% | -60.1% | -35.9% | |
| ROE | 38.1% | 34.6% | -15.4% | -52.3% | -30.3% | -43.9% | -33.9% | -69.8% | -67.8% | -75.6% | -64.6% | -37.6% | |
| ROIC | 24.0% | 27.6% | -20.4% | -56.5% | -31.6% | -45.8% | -35.4% | -51.9% | -87.5% | -52.9% | -82.6% | · |
Liquidité et Solvabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 | 6.8 | 10.2 | 8.8 | 7.6 | 12.9 | 10.0 | 20.5 | |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 | 3.5 | 3.0 | 2.7 | 1.8 | 4.0 | 4.7 | 3.9 |
Efficacité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 1.0 | 1.1 | 0.8 | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | 0.9 | 1.2 | 1.6 | 0.8 | 0.9 | 1.3 | 2.2 | · | 1.9 | 1.5 | · | · | |
| Receivables Turnover | 9.7 | 9.7 | 9.1 | 8.2 | 8.6 | 10.5 | 11.0 | 10.3 | 10.7 | 5.9 | · | · |
Par action
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.21 | $4.40 | $2.62 | $2.47 | $3.36 | $3.93 | $4.50 | $3.33 | $2.69 | $4.27 | $1.96 | $3.09 | |
| Revenue / Share | $6.31 | $5.76 | $4434.39 | $3199.07 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $0.65 | $0.95 | $101.95 | $-705.30 | · | · | · | · | · | · | · | · | |
| Cash / Share | $1.04 | $1.92 | $1.15 | $0.71 | $0.92 | $2.04 | $1.22 | $0.94 | $0.56 | $1.35 | $1.00 | $0.62 | |
| EPS (TTM) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · |
Taux de croissance
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.9% | 31.9% | 40.5% | 6.8% | 9.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.5% | 25.5% | 18.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.4% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 69.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 72.7% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Net Income TTM | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| Market Cap | $4.55B | $3.06B | $5.16B | $2.58B | $3.76B | $8.53B | $6.64B | $2.33B | $3.75B | $3.50B | $3.63B | $3.18B | |
| P/E | 11.6 | 13.5 | -84.6 | -11.9 | -22.2 | -29.9 | · | · | · | · | · | · | |
| P/S | 4.2 | 3.2 | 7.1 | 5.0 | 7.8 | 19.3 | 19.6 | 10.4 | 30.0 | 202.0 | 59575.7 | 26470.9 | |
| P/B | 3.7 | 4.2 | 11.9 | 6.4 | 6.9 | 13.6 | 9.5 | 4.9 | 11.2 | 6.8 | 18.2 | 10.3 | |
| P / Tangible Book | 4.1 | 5.0 | 14.1 | 6.4 | 6.9 | 13.6 | · | · | · | · | · | · | |
| P / Cash Flow | 41.4 | 19.4 | 308.7 | -22.6 | -29.9 | -62.7 | -44.0 | -13.9 | -17.2 | -16.6 | -29.8 | -47.8 | |
| P / FCF | 43.3 | 19.5 | 309.6 | -22.6 | -29.6 | -59.4 | -43.6 | -13.7 | -17.1 | -16.5 | -29.3 | -47.7 | |
| Earnings Yield | 8.6% | 7.4% | -1.2% | -8.4% | -4.5% | -3.4% | · | · | · | · | · | · |
Compte de résultat
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308M | $268M | $284M | $279M | $265M | $244M | $260M | $250M | $242M | $206M | $231M | $212M | $165M | $118M | $136M | $131M | |
| Cost of Revenue | $28M | $25M | $26M | $22M | $21M | $20M | $22M | $19M | $18M | $23M | $18M | $15M | $7M | $2M | $2M | $2M | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $213M | $197M | $158M | $117M | $134M | $129M | |
| R&D Expense | $82M | $77M | $85M | $88M | $78M | $78M | $101M | $67M | $76M | $60M | $67M | $157M | $59M | $69M | $76M | $81M | |
| SG&A Expense | $160M | $171M | $156M | $133M | $134M | $126M | $130M | $133M | $117M | $108M | $111M | $98M | $96M | $101M | $104M | $78M | |
| Operating Expenses | $270M | $273M | $267M | $243M | $232M | $225M | $106M | $219M | $212M | $191M | $196M | $269M | $162M | $172M | $183M | $162M | |
| Operating Income | $38M | $-5M | $17M | $36M | $32M | $19M | $154M | $32M | $30M | $15M | $35M | $-58M | $3M | $-54M | $-46M | $-31M | |
| Other Non-op | $647.0K | $542.0K | $596.0K | $593.0K | $594.0K | $588.0K | $575.0K | $576.0K | $386.0K | $286.0K | $0 | $2M | $-1M | $5M | $2M | $2M | |
| Pretax Income | $46M | $4M | $26M | $45M | $40M | $28M | $161M | $39M | $37M | $21M | $40M | $-52M | $6M | $-45M | $-41M | $-26M | |
| Income Tax | $15M | $344.0K | $-247M | $-27M | $14M | $9M | $17M | $6M | $4M | $4M | $-6M | $13M | $5M | $-2M | $835.0K | $768.0K | |
| Net Income | $32M | $4M | $274M | $72M | $27M | $19M | $144M | $33M | $33M | $17M | $46M | $-65M | $1M | $-43M | $-42M | $-27M | |
| EPS (Basic) | $0.18 | $0.02 | $1.62 | $0.43 | $0.16 | $0.11 | $0.87 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| EPS (Diluted) | $0.18 | $0.02 | $1.61 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| Shares (Basic) | 171,603,000 | 170,517,000 | · | 168,836,000 | 167,827,000 | 166,808,000 | · | 165,974,000 | 165,551,000 | 164,798,000 | · | 164,234,000 | 163,458,000 | 162,263,000 | · | 161,852 | |
| Shares (Diluted) | 172,851,000 | 172,706,000 | · | 170,650,000 | 168,681,000 | 167,668,000 | · | 166,178,000 | 166,174,000 | 166,623,000 | · | 164,234,000 | 165,046,000 | 162,263,000 | · | 161,852 | |
| EBITDA | $38M | $-5M | · | $36M | $32M | $19M | · | $32M | $30M | $15M | · | $-58M | $3M | $-54M | · | $-31M |
Bilan
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $385M | $282M | $178M | $258M | $254M | $218M | $320M | $155M | $177M | $205M | $189M | $98M | $108M | $291M | $115M | $155M | |
| Receivables | $151M | $135M | $121M | $116M | $108M | $106M | $99M | $98M | $104M | $95M | · | $93M | $82M | $66M | · | $56M | |
| Inventory | $109M | $112M | $111M | $106M | $111M | $103M | $92M | $87M | $86M | $67M | · | $25M | $14M | $11M | · | $12M | |
| Prepaid Expense | $69M | $65M | $60M | $61M | $53M | $53M | $56M | $52M | $46M | $43M | · | $38M | $24M | $24M | · | $23M | |
| Current Assets | $1.22B | $1.10B | $1.06B | $1.08B | $961M | $871M | $938M | $788M | $729M | $675M | · | $499M | $493M | $503M | · | $522M | |
| PP&E (Net) | $17M | $15M | $8M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $17M | · | · | · | $14M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $10M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $103M | $106M | $109M | $112M | $114M | $117M | $120M | $106M | $108M | $110M | · | $67M | $68M | $70M | · | · | |
| Other Non-current Assets | $4M | $4M | $4M | $3M | $2M | $1M | $359.0K | $359.0K | $476.0K | $476.0K | · | $475.0K | $11M | $12M | · | $6M | |
| Total Assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Accounts Payable | $45M | $12M | $11M | $22M | $20M | $18M | $16M | $19M | $20M | $19M | · | $12M | $19M | $17M | · | $10M | |
| Accrued Liabilities | $317M | $293M | $266M | $335M | $310M | $284M | $379M | $325M | $318M | $311M | · | $197M | $169M | $207M | · | $107M | |
| Current Liabilities | $361M | $306M | $277M | $357M | $330M | $303M | $395M | $344M | $338M | $331M | · | $210M | $188M | $224M | · | $117M | |
| Capital Leases | $60M | $39M | $41M | $43M | $45M | $45M | $42M | $40M | $47M | $49M | · | $48M | $50M | $51M | · | $54M | |
| Deferred Tax | · | · | $11M | · | · | · | $11M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $15M | $13M | $19M | $14M | $29M | $20M | $18M | $15M | $12M | $11M | · | $13M | $9M | $5M | · | $6M | |
| Total Liabilities | $436M | $357M | $337M | $413M | $403M | $367M | $455M | $400M | $397M | $391M | · | $270M | $247M | $281M | · | $177M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | · | $16.0K | $16.0K | $16.0K | · | $16.0K | |
| Retained Earnings | $-1.78B | $-1.81B | $-1.81B | $-2.09B | $-2.16B | $-2.19B | $-2.20B | $-2.35B | $-2.38B | $-2.41B | · | $-2.48B | $-2.41B | $-2.41B | · | $-2.33B | |
| AOCI | $-958.0K | $-563.0K | $1M | $989.0K | $406.0K | $437.0K | $292.0K | $858.0K | $-339.0K | $-229.0K | · | $-319.0K | $-535.0K | $-220.0K | · | $-1M | |
| Stockholders' Equity | $1.31B | $1.25B | $1.23B | $917M | $822M | $765M | $733M | $577M | $517M | $464M | $432M | $362M | $396M | $374M | $400M | $426M | |
| Liabilities + Equity | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Shares Outstanding | 172,132,442 | 171,086,205 | 170,309,376 | 169,146,043 | 168,607,881 | 167,116,045 | 166,708,856 | 166,351,715 | 165,853,301 | 164,959,736 | · | 163,968,949 | 163,355,787 | 162,384,178 | · | 161,871,806 |
Flux de trésorerie
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $17M | $15M | $13M | $13M | $14M | $11M | $10M | $26M | $16M | $15M | $18M | $19M | $15M | $15M | $14M | $18M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $2M | $2M | $5M | $1M | $1M | $1M | $0 | $0 | $0 | |
| Operating Cash Flow | $101M | $34M | $-49M | $74M | $64M | $20M | $40M | $63M | $25M | $29M | $85M | $-59M | $8M | $-18M | $-24M | $-727.0K | |
| CapEx | $5M | $5M | $4M | $388.0K | $297.0K | $0 | $453.0K | $70.0K | · | · | $0 | · | · | · | $0 | $0 | |
| Investing Cash Flow | $-9M | $66M | $-56M | $-79M | $-43M | $-124M | $122M | $-82M | $-56M | $-14M | $-347.0K | $34M | $-194M | $193M | $-18M | $15M | |
| Stock Issued | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Stock Activity | · | $4M | · | · | · | $2M | · | · | · | $1M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Change in Cash | $103M | $105M | $-82M | $4M | $37M | $-102M | $164M | $-19M | $-28M | $16M | $90M | $-12M | $-181M | $176M | $-40M | $15M | |
| Free Cash Flow | · | $29M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Rentabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| Net Margin | 10.2% | 1.4% | · | 25.8% | 10.1% | 7.8% | · | 13.1% | 13.8% | 8.0% | · | -30.8% | 0.67% | -36.3% | · | -20.8% | |
| Pretax Margin | 15.1% | 1.5% | · | 16.0% | 15.2% | 11.4% | · | 15.5% | 15.4% | 10.2% | · | -24.6% | 3.8% | -37.9% | · | -20.2% | |
| EBITDA Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| ROA | 2.1% | 0.27% | · | 6.2% | 2.5% | 1.9% | · | 4.1% | 4.3% | 2.2% | · | -10.5% | 0.18% | -6.7% | · | -4.1% | |
| ROE | 3.0% | 0.36% | · | 9.6% | 4.0% | 3.1% | · | 7.0% | 7.3% | 4.0% | · | -16.6% | 0.27% | -10.5% | · | -5.5% | |
| ROIC | 2.0% | -0.34% | · | 6.3% | 2.6% | 1.7% | · | 4.6% | 5.3% | 2.6% | · | -19.9% | 0.13% | -13.7% | · | -7.5% |
Liquidité et Solvabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.6 | · | 3.0 | 2.9 | 2.9 | · | 2.3 | 2.2 | 2.0 | · | 2.4 | 2.6 | 2.2 | · | 4.5 | |
| Quick Ratio | 1.5 | 1.4 | · | 1.0 | 1.1 | 1.1 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | 1.0 | 1.6 | · | 1.8 |
Efficacité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.6 | · | 0.8 | 0.6 | 0.1 | · | 0.2 | |
| Receivables Turnover | 2.4 | 2.2 | · | 2.6 | 2.5 | 2.4 | · | 2.6 | 2.6 | 2.6 | · | 2.9 | 2.2 | 1.8 | · | 2.2 |
Par action
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.59 | $7.29 | · | $5.42 | $4.88 | $4.58 | · | $3.47 | $3.12 | $2.81 | · | $2.21 | $2.42 | $2.30 | · | $2.63 | |
| Revenue / Share | $1.78 | $1.55 | · | $1.63 | $1.57 | $1.46 | · | $1.51 | $1.46 | $1.24 | · | $1289.01 | $1001.15 | $0.73 | · | $807.61 | |
| Cash Flow / Share | · | $0.20 | · | · | · | $0.12 | · | · | · | $0.17 | · | · | · | $-0.11 | · | · | |
| Cash / Share | $2.24 | $1.65 | · | $1.53 | $1.50 | $1.30 | · | $0.93 | $1.07 | $1.24 | · | $0.60 | $0.66 | $1.79 | · | $0.96 | |
| EPS (TTM) | $2.23 | $2.21 | · | $1.55 | $1.33 | $1.37 | · | $0.79 | $0.19 | $0.00 | · | $-0.92 | $-0.69 | $-0.91 | · | $-1.35 |
Valorisation (TTM)
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.14B | $1.10B | · | $1.05B | $1.02B | $996M | · | $929M | $891M | $814M | · | $632M | $551M | $520M | · | $512M | |
| Net Income TTM | $380M | $376M | · | $261M | $222M | $229M | · | $129M | $31M | $-2M | · | $-149M | $-111M | $-146M | · | $-217M | |
| Market Cap | $4.35B | $3.81B | · | $3.61B | $3.64B | $2.78B | · | $2.56B | $2.70B | $3.05B | · | $3.42B | $3.91B | $3.06B | · | $2.65B | |
| P/E | 11.3 | 10.1 | · | 13.8 | 16.2 | 12.1 | · | 19.5 | 85.5 | · | · | -22.7 | -34.7 | -20.7 | · | -12.1 | |
| P/S | 3.8 | 3.5 | · | 3.4 | 3.6 | 2.8 | · | 2.8 | 3.0 | 3.7 | · | 5.4 | 7.1 | 5.9 | · | 5.2 | |
| P/B | 3.3 | 3.1 | · | 3.9 | 4.4 | 3.6 | · | 4.4 | 5.2 | 6.6 | · | 9.4 | 9.9 | 8.2 | · | 6.2 | |
| P / Tangible Book | 3.6 | 3.3 | · | 4.5 | 5.1 | 4.3 | · | 5.4 | 6.6 | 8.6 | · | 11.6 | 11.9 | 10.0 | · | 6.2 | |
| P / Cash Flow | · | 112.1 | · | · | · | 136.6 | · | · | · | 104.9 | · | · | · | -170.4 | · | · | |
| Earnings Yield | 8.8% | 9.9% | · | 7.3% | 6.2% | 8.2% | · | 5.1% | 1.2% | 0.00% | · | -4.4% | -2.9% | -4.8% | · | -8.2% |
Période la plus récente à gauche · valeurs nulles affichées comme ·
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenu | $1.07B | $958M | $726M | $517M | $484M |
| Marge Brute % | · | · | 94.3% | 98.0% | 97.8% |
| Marge d'exploitation % | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| Résultat net | $391M | $226M | $-61M | $-216M | $-168M |
| BPA dilué | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio de liquidité | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 |
| Ratio de liquidité réduite | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $105M | $157M | $17M | $-114M | $-127M |
Détenteurs institutionnels (13F) 385 déclarants · $4.7B total · Au 30 septembre 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Détenteurs
385
Valeur détenue
$4.7B
Nouvelles positions
49
Positions clôturées
36
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 49 (-4 vs T. préc.) | 36 (+8 vs T. préc.) | 135 (+15 vs T. préc.) | 115 (-7 vs T. préc.) | +4.6M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $1 085 696 471 | 42 912 904 | 23,31% | Actions |
| BlackRock, Inc. | $569 633 876 | 22 515 173 | 12,23% | Actions |
| VANGUARD GROUP INC | $404 762 192 | 15 153 957 | 8,69% | Actions |
| STATE STREET CORP | $229 628 164 | 9 076 212 | 4,93% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $223 612 785 | 8 838 450 | 4,80% | Actions |
| RTW INVESTMENTS, LP | $180 756 457 | 7 144 524 | 3,88% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $145 822 875 | 5 763 750 | 3,13% | Actions |
| DIMENSIONAL FUND ADVISORS LP | $93 482 749 | 3 694 988 | 2,01% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $84 977 229 | 3 358 129 | 1,82% | Actions |
| Palo Alto Investors LP | $72 461 629 | 2 864 096 | 1,56% | Actions |
| GOLDMAN SACHS GROUP INC | $65 276 910 | 2 580 115 | 1,40% | Actions |
| Qube Research & Technologies Ltd | $61 899 233 | 2 446 610 | 1,33% | Actions |
| Point72 Asset Management, L.P. | $61 559 150 | 2 433 168 | 1,32% | Actions |
| CITADEL ADVISORS LLC | $55 209 078 | 2 182 177 | 1,19% | Actions |
| Pictet Asset Management Holding SA | $50 146 450 | 1 983 198 | 1,08% | Actions |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $49 826 959 | 1 969 445 | 1,07% | Actions |
| MARSHALL WACE, LLP | $44 650 402 | 1 764 838 | 0,96% | Actions |
| D. E. Shaw & Co., Inc. | $42 957 806 | 1 697 937 | 0,92% | Actions |
| BRAIDWELL LP | $41 653 895 | 1 646 399 | 0,89% | Actions |
| NORGES BANK | $41 069 692 | 1 623 308 | 0,88% | Actions |
| Frazier Life Sciences Management, L.P. | $36 386 409 | 1 438 198 | 0,78% | Actions |
| NORTHERN TRUST CORP | $34 595 776 | 1 367 422 | 0,74% | Actions |
| Nuveen, LLC | $34 109 259 | 1 348 192 | 0,73% | Actions |
| Artisan Partners Limited Partnership | $33 525 890 | 1 325 134 | 0,72% | Actions |
| BANK OF AMERICA CORP /DE/ | $32 899 740 | 1 300 385 | 0,71% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $32 449 679 | 1 282 596 | 0,70% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $30 520 301 | 1 206 336 | 0,66% | Actions |
| Allspring Global Investments Holdings, LLC | $28 540 663 | 1 132 566 | 0,61% | Actions |
| Rockefeller Capital Management L.P. | $25 690 127 | 1 015 420 | 0,55% | Actions |
| MORGAN STANLEY | $23 949 976 | 946 639 | 0,51% | Actions |
| TWO SIGMA INVESTMENTS, LP | $23 452 898 | 926 992 | 0,50% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $23 082 961 | 912 370 | 0,50% | Actions |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $21 642 506 | 855 435 | 0,46% | Actions |
| Invesco Ltd. | $20 504 689 | 810 462 | 0,44% | Actions |
| PRINCIPAL FINANCIAL GROUP INC | $19 966 658 | 789 196 | 0,43% | Actions |
| Bank of New York Mellon Corp | $19 243 919 | 760 629 | 0,41% | Actions |
| Allianz Asset Management GmbH | $19 157 034 | 757 195 | 0,41% | Actions |
| PANAGORA ASSET MANAGEMENT INC | $17 985 922 | 710 906 | 0,39% | Actions |
| Fisher Asset Management, LLC | $17 690 535 | 699 230 | 0,38% | Actions |
| FRED ALGER MANAGEMENT, LLC | $16 409 858 | 648 611 | 0,35% | Actions |
| RICE HALL JAMES & ASSOCIATES, LLC | $15 657 841 | 618 887 | 0,34% | Actions |
| AMERIPRISE FINANCIAL INC | $15 348 144 | 606 536 | 0,33% | Actions |
| MILLENNIUM MANAGEMENT LLC | $14 925 077 | 589 924 | 0,32% | Actions |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $14 771 456 | 583 852 | 0,32% | Actions |
| AQR CAPITAL MANAGEMENT LLC | $13 225 551 | 522 749 | 0,28% | Actions |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $12 903 000 | 510 000 | 0,28% | Actions |
| GLENMEDE TRUST CO NA | $12 360 212 | 488 546 | 0,27% | Actions |
| Hudson Bay Capital Management LP | $11 764 500 | 465 000 | 0,25% | Actions |
| UBS Group AG | $11 639 341 | 460 053 | 0,25% | Actions |
| JUPITER ASSET MANAGEMENT LTD | $11 599 190 | 458 466 | 0,25% | Actions |
Activistes et détenteurs de 5%+ 6 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB3 LLC ×14 dépôts | 26 février 2026 | 25,40% | Amendement | · | SEC |
| Baker Bros. Advisors, LLC, Felix J. Baker, Julian C. Baker ×4 dépôts | 6 juin 2013 | · | Dépôt initial | · | SEC |
| Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée | 2 mai 2005 | · | Dépôt initial | · | SEC |
| Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée | 2 mai 2005 | · | Dépôt initial | · | SEC |
| Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée | 2 mai 2005 | · | Dépôt initial | · | SEC |
| Oxford Bioscience Partners IV L.P., mRNA Fund II L.P., OBP Management IV L.P., Jeffrey T. Barnes, Mark P. Carthy, Jonathan J. Fleming, Michael E. Lytton, Alan G. Walton | 29 avril 2005 | · | Dépôt initial | Investissement passif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Initiés de la société 42 initiés · 24 dirigeants · 21 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Adams Catherine Owen | Chief Executive Officer | 24 mars 2026 M | 14 803 | 0 | 1 | $-249 932 |
| Stephen Davis | CEO | 19 août 2024 S | 186 555 | 0 | 0 | $0 |
| Uli Hacksell | CEO | 17 février 2015 M | 115 549 | 0 | 0 | $0 |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | 6 août 2026 M | 67 828 | 0 | 9 | $-1 126 027 |
| Elena Ridloff | EVP and CFO | 29 avril 2021 M | 10 553 | 0 | 0 | $0 |
| Todd S. Young | EVP AND CFO | 15 octobre 2018 A | · | 0 | 0 | $0 |
| Thomas H Aasen | EXEC VP, CFO AND CBO | 4 avril 2014 M | 0 | 0 | 0 | $0 |
| Srdjan R. Stankovic | President | 21 novembre 2022 M | 61 234 | 0 | 0 | $0 |
| Mark R Brann | President & CSO | 16 juin 2006 S | 317 756 | 0 | 0 | $0 |
| Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | 17 novembre 2024 M | 62 105 | 0 | 0 | $0 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 29 juillet 2026 M | 18 994 | 0 | 3 | $-506 411 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 26 juin 2026 S | 13 088 | 0 | 8 | $-602 789 |
| Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | 24 mars 2026 M | 11 280 | 0 | 2 | $-245 022 |
| Thomas Garner | EVP, Chief Commercial Officer | 6 mars 2026 A | · | 0 | 0 | $0 |
| Austin D. Kim | EVP,General Counsel, Secretary | 6 janvier 2024 M | 46 901 | 0 | 0 | $0 |
| Douglas J Williamson | Executive VP, Research & Dev | 10 février 2023 A | · | 0 | 0 | $0 |
| Michael J. Yang | EVP and CCO | 6 janvier 2021 M | 8 059 | 0 | 0 | $0 |
| Eric Alejandro Miller | Controller & PAO | 15 octobre 2019 M | 270 | 0 | 0 | $0 |
| Glenn Baity | EVP AND GC | 18 avril 2018 A | 83 734 | 0 | 0 | $0 |
| Terrence O Moore | EVP, CHIEF COMMERCIAL OFFICER | 8 mars 2017 A | 1 671 | 0 | 0 | $0 |
| Roger Mills | EVP, DEVELOPMENT AND CMO | 20 mars 2015 A | 18 550 | 0 | 0 | $0 |
| Bo-Ragnar Tolf | VP/Mg. Dir. ACADIA Pharma AB | 8 juillet 2009 M | 20 000 | 0 | 0 | $0 |
| Brian Lundstrom | Sr. VP, Bus. Development | 7 mars 2008 A | 0 | 0 | 0 | $0 |
| Robert E Davis | Exec. VP, Drug Discovery | 11 mars 2005 A | · | 0 | 0 | $0 |
| Adora Ndu | Administrateur | 29 mai 2026 A | 32 908 | 0 | 0 | $0 |
| Elizabeth A. Garofalo | Administrateur | 29 mai 2026 A | 33 489 | 0 | 0 | $0 |
| Jonathan Poole | Administrateur | 29 mai 2026 A | 2 010 | 0 | 0 | $0 |
| James M Daly | Administrateur | 29 mai 2026 A | 12 148 | 0 | 1 | $-671 100 |
| Laura Brege | Administrateur | 29 mai 2026 A | 23 202 | 0 | 0 | $0 |
| Edmund Harrigan | Administrateur | 29 mai 2026 A | 43 148 | 0 | 0 | $0 |
| Daniel B Soland | Administrateur | 29 mai 2025 A | 44 041 | 0 | 0 | $0 |
| Mary Ann Gray | Administrateur | 7 juin 2016 M | 149 476 | 0 | 0 | $0 |
| Leslie L Iversen | Administrateur | 18 avril 2016 M | 36 127 | 0 | 0 | $0 |
| Lester J Ph D Kaplan | Administrateur | 11 août 2015 M | 17 000 | 0 | 0 | $0 |
| William Mcdowall Wells | Administrateur | 15 juin 2015 A | 0 | 0 | 0 | $0 |
| Torsten Rasmussen | Administrateur | 15 juin 2015 A | 8 500 | 0 | 0 | $0 |
| Michael T Borer | Administrateur | 15 juin 2015 A | 0 | 0 | 0 | $0 |
| Gordon M Binder | Administrateur | 12 juin 2009 A | 14 364 | 0 | 0 | $0 |
| Alan G Walton | Administrateur | 12 juin 2009 A | 25 979 | 0 | 0 | $0 |
| Martien Van Osch | Administrateur | 10 juin 2005 A | 1 168 892 | 0 | 0 | $0 |
| GORDON CARL L | Administrateur | 20 avril 2005 A | 774 006 | 0 | 0 | $0 |
| John Joseph Kaiser | · | 20 octobre 2008 A | · | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 59 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| IBRN · iShares Trust | 4,92% | 13 265 SH | 11 septembre 2026 | Quotidien |
| PBE · Invesco Exchange-Traded Fund Trust | 1,84% | 383 853 SH | 2 octobre 2026 | Quotidien |
| BBP · ETFis Series Trust I | 1,69% | 64 350 NS | 31 juillet 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,40% | 122 788 SH | 2 octobre 2026 | Quotidien |
| RZG · Invesco Exchange-Traded Fund Trust | 0,96% | 57 480 SH | 2 octobre 2026 | Quotidien |
| LABU · Direxion Shares ETF Trust | 0,71% | 134 777 NS | 31 juillet 2026 | N-PORT |
| ROSC · Lattice Strategies Trust | 0,62% | 14 725 NS | 31 juillet 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,35% | 150 827 SH | 19 août 2026 | Quotidien |
| IBB · iShares Trust | 0,35% | 1 293 913 SH | 11 septembre 2026 | Quotidien |
| IWO · iShares Trust | 0,24% | 1 215 092 SH | 11 septembre 2026 | Quotidien |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,23% | 12 181 SH | 2 octobre 2026 | Quotidien |
| PWS · Pacer Funds Trust | 0,20% | 1 841 NS | 31 juillet 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,19% | 137 860 SH | 19 août 2026 | Quotidien |
| BKSE · BNY Mellon ETF Trust | 0,19% | 6 256 NS | 31 juillet 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,17% | 443 221 SH | 19 août 2026 | Quotidien |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,17% | 19 976 SH | 2 octobre 2026 | Quotidien |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,16% | 36 279 NS | 31 juillet 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,13% | 34 493 NS | 31 juillet 2026 | N-PORT |
| IWM · iShares Trust | 0,12% | 3 296 450 SH | 11 septembre 2026 | Quotidien |
| ISCG · iShares Trust | 0,12% | 40 348 SH | 11 septembre 2026 | Quotidien |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,10% | 137 841 SH | 2 octobre 2026 | Quotidien |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,10% | 741 237 SH | 19 août 2026 | Quotidien |
| DFAS · Dimensional ETF Trust | 0,09% | 559 090 NS | 31 juillet 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,09% | 1 699 377 SH | 19 août 2026 | Quotidien |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,08% | 40 712 NS | 31 juillet 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,05% | 52 513 SH | 2 octobre 2026 | Quotidien |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 10 893 NS | 31 juillet 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,05% | 2 295 NS | 31 juillet 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,04% | 54 681 NS | 31 juillet 2026 | N-PORT |
| IEUS · iShares Trust | 0,04% | 7 263 SH | 11 septembre 2026 | Quotidien |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1 457 036 SH | 19 août 2026 | Quotidien |
| VB · VANGUARD INDEX FUNDS | 0,04% | 2 944 095 SH | 19 août 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | 0,04% | 346 329 SH | 19 août 2026 | Quotidien |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,04% | 13 154 SH | 2 octobre 2026 | Quotidien |
| WSML · iShares Trust | 0,04% | 11 751 SH | 11 septembre 2026 | Quotidien |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 4 009 SH | 2 octobre 2026 | Quotidien |
| DXUV · Dimensional ETF Trust | 0,02% | 5 018 NS | 31 juillet 2026 | N-PORT |
| ISCF · iShares Trust | 0,02% | 13 099 SH | 11 septembre 2026 | Quotidien |
| DFUV · Dimensional ETF Trust | 0,02% | 113 182 NS | 31 juillet 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 348 929 NS | 31 juillet 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,02% | 103 974 NS | 31 juillet 2026 | N-PORT |
| SCZ · iShares Trust | 0,02% | 238 968 SH | 9 septembre 2026 | Quotidien |
| DCOR · Dimensional ETF Trust | 0,01% | 16 150 NS | 31 juillet 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,01% | 28 150 SH | 19 août 2026 | Quotidien |
| DFAU · Dimensional ETF Trust | 0,01% | 39 121 NS | 31 juillet 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 35 516 SH | 10 septembre 2026 | Quotidien |
| ITOT · iShares Trust | 0,00% | 161 527 SH | 11 septembre 2026 | Quotidien |
| DFUS · Dimensional ETF Trust | 0,00% | 35 634 NS | 31 juillet 2026 | N-PORT |
| IEFA · iShares Trust | 0,00% | 240 578 SH | 11 septembre 2026 | Quotidien |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31 juillet 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4 075 731 SH | 19 août 2026 | Quotidien |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 100 076 SH | 19 août 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 10 781 SH | 19 août 2026 | Quotidien |
| IJR · iShares Trust | · | 7 728 763 SH | 10 septembre 2026 | Quotidien |
| IJT · iShares Trust | · | 1 198 794 SH | 9 septembre 2026 | Quotidien |
| XJR · iShares Trust | · | 17 544 SH | 31 août 2026 | Quotidien |
| ISCB · iShares Trust | · | 5 636 SH | 11 septembre 2026 | Quotidien |
| SMLF · iShares Trust | · | 221 806 SH | 11 septembre 2026 | Quotidien |
| SMMV · iShares Trust | · | 16 924 SH | 19 août 2026 | Quotidien |
ACAD Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
notation · 27 analystes
ACHAT
Objectif médian
$33.00
+65,4%
7 25,9%
Achat fort
14 51,9%
Achat
5 18,5%
Conserver
1 3,7%
Vente
0 0,0%
Vente forte
Objectif de cours à 12 mois
19 analystes · 2026-09-29Objectif moyen $32.16 +61,2%
Maintenant
Prix actuel $19.95
Bas$17.00
Moyenne$32.16
Haut$49.00
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | · |
| IDYA | $3.04B | -27.0 | 3024.4% | -52.0% | -11.5% | · |
| VCYT | $3.34B | 51.3 | 16.0% | 12.8% | 5.2% | 70.1% |
| CELC | $4.81B | -26.3 | · | · | -244.3% | · |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | · |
| DNLI | $2.58B | -5.6 | 204.7% | · | -50.2% | · |
| RCUS | $2.99B | -7.2 | -4.3% | -142.9% | -59.8% | · |
| ARQT | $3.58B | -223.4 | 91.3% | -4.3% | -9.8% | · |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | · |
| PURR | $1.58B | 2.5 | · | 3229.8% | 24.8% | · |
| DYN | $3.23B | -5.6 | · | · | -57.8% | · |
Dernières actualités Actualités récentes mentionnant cette entreprise
Signaux de trading Signaux d'achat/vente récents avec prix d'entrée et ratio risque/récompense
BLUECHIP_DIP
Expiré
risque 1
récompense 5,00
entrée
$21.20
R:R 5,00
BLUECHIP_DIP
Stop sorti
risque 1
récompense 4,79
entrée
$21.86
R:R 4,79
BLUECHIP_DIP
Stop sorti
risque 1
récompense 4,99
entrée
$22.45
R:R 4,99
Aucun signal ouvert pour le moment — aucune carte n'est remplie, et c'est honnête.
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Source : Dépôt SEC 10-Q le Aoû 5, 2026